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Introduction 
Cutaneous melanoma is the most common cause of skin cancer 
mortality.1 Although only 5% of skin cancers are melanomas, 
it accounts for more than 50% of skin cancer deaths.2 There 
is a rising incidence of melanoma reported worldwide.1-4 A 
study in Cape Town identified its white sub-population as 
having amongst the highest incidence in the world for primary 
melanoma.3
Primary melanoma develops most commonly on the 
skin and its pattern of spread is usually via lymphatics to 
regional lymph nodes or via haematogenous spread to distant 
metastatic sites including lung, liver, brain, peripheral nerves, 
skin and soft tissue.4 
Advanced melanoma includes American Joint Committee on 
Cancer (AJCC) 7th Edition5 stage III and IV and encompasses 
melanoma with nodal or distant spread. It is associated with a 
particularly poor prognosis, and early diagnosis and accurate 
staging affect prognosis and survival.1, 6
In advanced melanoma, surgery is the most effective means 
of achieving loco-regional control.7 It remains the standard 
approach for patients with regional nodal metastases, provided 
it does not lead to unacceptable morbidity and mortality. 
In selected cases, surgery can provide distant control and 
metastasectomy has been associated with improved overall 
survival in stage IV melanoma.4,6-8
Accurate preoperative staging is essential to ascertain 
which patients may benefit from further surgery after initial 
diagnostic biopsy.4,7 It allows for subsequent surgical control 
of limited loco-regional disease and avoids the morbidity of 
lymph node dissection in inappropriately selected patients, 
including those with unresectable loco-regional disease or 
occult distant metastases.4
PET-CT has been shown to exclude other sites of metastatic 
disease and aid in surgical planning both in stage III and 
potentially resectable stage IV disease.2 Current guidelines 
endorse the use of PET-CT staging in stage III and IV 
melanoma and do not recommend PET-CT staging in early 
melanoma (stage I and II).9
The utility of PET-CT in the staging and 
management of advanced and recurrent 
malignant melanoma
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Background: Accurate pre-operative staging and correct surgical selection of patients with malignant melanoma reduces 
unnecessary  morbidity and mortality, improves distant control and may improve survival. 18F-fluorodeoxyglucose Positron 
Emission Tomography Computed Tomography (18F-FDG PET-CT) has been shown to be useful in exclusion of metastatic 
sites and aids in surgical planning in stage III and potentially resectable stage IV disease. The primary objective of the 
study was to determine whether the use of PET-CT alters the initial staging and management of patients with advanced and 
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Methods: Retrospective analysis of clinical records of patients with malignant melanoma referred for staging PET-CT over 
a three-year period at our institution was performed. Pre- and post-PET-CT stage was recorded and a descriptive analysis 
was done to determine whether PET-CT resulted in a change in stage grouping and whether this change effected a change in 
clinical management. 
Results: A change in stage grouping occurred in 21/39 (53.8%) of patients, 76.2% of which were up-staged and 23.8% down 
staged. On analysis of stage III/IV and recurrent melanoma, a change in stage occurred in 90% of stage III, 50% of stage IV 
and 50% of recurrent melanoma patients. This effected a change in management in 86.7% of patients with stage III, IV and 
recurrent melanoma collectively.
Conclusion: PET-CT is a useful tool in the staging and subsequent management of melanoma. Its utility is pronounced in 
advanced and recurrent melanoma. 
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The diagnostic accuracy and the value of PET is highest 
in higher stages of melanoma, in the setting of macroscopic 
nodal disease (stage IIIB and higher).6,10 In a systematic 
review, PET sensitivity has been reported to be 68–87% for 
stage III and IV melanoma compared to 0–67% for stage I and 
II melanoma.10 In a small study of 33 patients by Horn et al., 
12% of patients had true melanoma metastases identified on 
PET, none of which were identified by conventional imaging. 
The PET findings upgraded staging in these patients from 
stage III to IV.1,11
In our resource-limited setting, the obligation exists for 
judicious use of PET-CT directed by both comprehensive 
assessment of its utility in preoperative staging, and 
assessment of the effect of its use on clinical management 
decisions. Clear guidelines for its use are necessary to 
facilitate appropriate evidence-based and context appropriate 
care via the multidisciplinary team.
The primary objective of this study was to determine 
whether PET-CT alters staging and management in advanced 
and recurrent melanoma. 
Methods
A retrospective analysis of clinical records of patients with 
malignant melanoma referred for staging PET-CT over a 
three-year period from February 2012 to February 2015 was 
performed. Patients included in the analysis were those with 
histologically confirmed cutaneous malignant melanoma and 
clinically evident Stage I-IV or recurrent disease referred 
for PET-CT at The Western Cape Academic PET-CT Centre, 
Cape Town, South Africa. Patients referred for PET-CT 
from health care institutions other than our institution were 
excluded from the analysis, due to unavailability of post-PET-
CT clinical records.  Further exclusions included patients with 
an additional primary cancer other than melanoma or basal 
cell carcinoma (diagnosed within five years after melanoma 
diagnosis), patients younger than 18 years of age, choroidal 
or conjunctival melanoma, and those with incomplete clinical 
records.
The study was conducted with the approval of the 
Stellenbosch University Human Research Ethics Committee, 
as well as the institutional review board of the hospital (HREC 
reference number S15/10/252).
Sampling was conducted with the permission and use of 
records from the Western Cape Academic PET-CT Centre 
database. Data from the clinical records of the identified 
referrals was reviewed with the aid of electronic databases, 
including the National Health Laboratory System (NHLS), 
the Tygerberg Hospital Enterprise Content Management 
(ECM) System and the Picture Archiving and Communication 
System (PACS). Where electronic data was not available, hard 
copy clinical records were reviewed. Patient characteristics 
including age, gender, HIV status and serum lactase 
dehydrogenase (LDH) were recorded. Ethnicity, although 
important, was poorly recorded and hence not captured.
Tumour characteristics including tumour, nodal and 
metastasis (TNM) and AJCC staging were recorded. 
Histological subtypes were grouped for analysis into non-
acral lentiginous cutaneous, acral lentiginous cutaneous, 
mucosal and unknown subtype. Melanoma sites were grouped 
for analysis into trunk, limbs, head and neck, mucosal or 
nodal. Nodal sites were defined as pathologically confirmed 
melanoma in a lymph node, without a primary site identified. 
Baseline imaging included a combination of chest x-ray 
(CXR) and ultrasound scan (USS) of the abdomen or CT scan 
of the chest and abdomen.
18F-FDG PET-CT scans were performed as per Tygerberg 
Hospital/Stellenbosch University nuclear medicine protocols, 
an adaptation of European Association of Nuclear Medicine 
(EANM) procedure guidelines.12 Scans were interpreted 
visually by an experienced nuclear medicine physician in 
consultation with a qualified radiologist. PET-CT reports with 
imaging findings interpreted as ‘suspicious for’ or ‘consistent 
with’ were considered positive for occult metastatic disease. 
This is consistent with studies performed elsewhere.8
Pre- and post-FDG PET-CT TNM staging was captured 
and analysed according to AJCC 7th Edition staging.5 Tumour 
stage included Breslow thickness and the presence or absence 
of ulceration. AJCC stage groupings were used to categorise 
patients into pre- and post-FDG PET-CT stage groups. 
Recurrence (local and regional) was documented as a separate 
stage entity, irrespective of TNM stage or AJCC stage group. 
It was further documented whether PET-CT resulted in a 
change in stage grouping and whether the change in stage 
grouping effected a change in clinical management.
Stage III, IV and recurrent melanomas were analysed 
separately, in keeping with the primary objective of the study.
Simple descriptive analysis was performed. 
Results
Exclusions
Of the 66 patients referred for FDG PET-CT at Tygerberg 
Hospital over the three-year period, 27 were excluded from 
the analysis. The study cohort therefore comprised 39 patients. 
Reasons for exclusion are documented in Table 1.
Table 1: Exclusions
Exclusion reason n (%)
1. Incomplete clinical records
2. Patients not referred via the radiation 
oncology dermatology MDT
3. Synchronous primary (non-BCC)
4. Previously captured in data-set
5. Not a melanoma primary
6. Lost to follow-up
7. Choroidal/conjunctival melanoma












MDT, multidisciplinary team; BCC, basal cell carcinoma
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Patient characteristics
Patient characteristics are shown in Table 2.  
Table 2: Patient characteristics
Age
Mean age (range) years 57 (24–84)
























Twenty-three (59.0%) of the analysed subset (n=39) had 
melanoma of the limbs. The number of patients with truncal 
melanoma was eight (20.5%), head and neck three (7.7%), 
primary nodal three (7.7%), and mucosal membranes two 
(5.1%). Histological subtypes are shown in Table 3. 
Table 3: Histological subtype











Pre-PET-CT TNM and AJCC stage grouping are documented 
in Table 4. Baseline imaging used pre-PET-CT included a 
combination of CXR and USS of the abdomen or computed 
tomography (CT) scans of the chest and abdomen. This 
was not standardised in all patients. Six (15.4%) patients 
had a combination of CXR and abdominal USS at baseline. 
According to previous protocols in the department this was the 
routine minimum investigation prior to clinical management 
decision making. Only two (5.1%) patients had a baseline 
contrasted CT of the chest and abdomen.
Histopathologically confirmed T4 tumours accounted for 11 
(28.2%) of the 39 patients.
Prior to PET-CT 18 (46.2%) patients were found to be 
cN0. One patient  had negative sentinel lymph node biopsy 
(SLNB). This can be ascribed to delay in referral for PET-
CT. Strict protocol for PET-CT was not in place at the time 
of referral. 
Prior to PET-CT staging, one (2.6%), four (10.3%), seven 
(17.9%), ten (25.6%), and eight (20.5%) patients accounted 
for stage 0, I, II, III, and IV respectively. There were four 
(10.3%) recurrences and five (12.8%) of unknown stage 
group.
Post PET-CT stage grouping was as follows: two (5.1%), 
five (12.8%), six (15.4%), 4 (10.3%) and 18 (46.2%) patients 
Table 4: Pre-PET-CT TNM and AJCC stage grouping 
Tumour characteristics:


































































* Recurrence is not part of TNM staging and in the study included local 
and nodal recurrences, but not metastatic progression 
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accounted for stage group 0, I, II, III and IV respectively. 
There were two (5.1%) recorded recurrences and two (5.1%) 
patients with unknown stage grouping.
The effect of PET-CT on stage grouping (Table 5)
In the entire cohort, 16 (41.0%) patients were upstaged 
and 5 (12.8%) down-staged after PET-CT staging. In stage 
0-II patients, a change in stage occurred in 3/12 (25.0%) of 
patients. In the clinical stage III/IV and recurrence group, 
a change in stage occurred in 15/22 (68.2%) patients. Ten 
(45.5%) cases were upstaged, and five (22.7%) down-staged 
in this group.




Stage 0-II 3 (25%) n/a 9 (75%) 12
Stage III 8 (80%) 1 (10%) 1 (10%) 10
Stage IV n/a 4 (50%) 4 (50%) 8
Recurrence 2 (50%) 0 2 (50%) 4
Unknown 3 (60%) 0 2 (40%) 5
TOTAL 16 (41.0%) 5 (12.8%) 18 (46.2%) 39 (100%)
n/a, not applicable
The effect of PET-CT in changing management
Of those with an altered stage in the III/IV and recurrence 
group (n=15), 13 (86.7%) had a change in management. 
Definitive surgery was cancelled in six (46.1%) patients and 
the management plans of four (30.8%) patients now included 
surgery. This had not been the plan prior to  PET-CT. One of 
these four patients had melanoma of the back with clinically 
palpable axillary lymph nodes and subcutaneous nodules. 
PET-CT excluded disseminated subcutaneous nodules and the 
patient was down-staged from stage IV to IIIc and went on to 
have a wide local excision (WLE) and axillary lymph node 
dissection (ALND). The second patient had melanoma of the 
left upper arm with bilateral axillary lymph nodes palpable 
and a raised LDH. PET-CT excluded the lymphadenopathy 
and the patient was down-staged from stage IV to IIB, with 
a subsequent plan for WLE and SLNB. A third patient had 
melanoma of the left forearm with bilateral axillary lymph 
nodes and a raised LDH. PET-CT excluded lymphadenopathy 
and downstaging from stage IV to IIB  led to a WLE and 
ALND. Notably SLNB is current protocol for this stage. 
The fourth patient had an unknown Breslow thickness but 
clinically palpable lymphadenopathy, satellite lesions and 
a suspicious lung lesion. Regional and distant metastatic 
spread were excluded with PET-CT and the patient was down-
staged from stage IV to N0M0 (Stage I-II) disease and WLE 
and SLNB were performed. Other changes in management 
included cancellation of lymph node dissection in one (7.7%) 
patient, further investigations  performed prior to further 
management in one patient and in one patient surgery was 
declined.
Discussion
Our study suggests that staging PET-CT is responsible for a 
change in stage in the majority of melanoma cases. In keeping 
with other studies, the effect is more pronounced in advanced 
melanoma.2,10,13-15 PET-CT staging in this group is endorsed by 
current South African guidelines.9
A change in AJCC stage group with PET-CT was detected 
in 53.8% of the entire group of patients and in 68.2% when 
the stage III/IV/recurrence group was analysed separately. 
Of those who had a change in stage in this sub-group, a large 
proportion (86.7%) had a management change. 
Controversy exists as to the utility of PET as part of 
preoperative staging in early stage melanoma.2,14,16,17 
There is little data to support the routine use of PET over 
conventional imaging such as chest x-ray (CXR) and 
computed tomography (CT) in all stages of melanoma. Most 
studies show low sensitivity in detecting distant disease in 
patients with clinically localized disease and PET is not 
routinely indicated for early stage disease. 2,13-15 To date it has 
been shown that PET-CT has a limited role in N0 disease. In 
patients without clinical evidence of nodal metastases, SLNB 
is the gold standard staging procedure. It is associated with 
high sensitivity and specificity, limited morbidity and high 
prognostic significance.4,13,18 
In this study 12  patients with N0M0 (stage 0-II) disease 
were referred for PET-CT and only 5 (41.7%) of these had T4 
disease. One was referred for PET-CT despite negative SLNB, 
which is the staging procedure of choice in N0 disease. It is 
the policy of the study institution to limit referral for PET-
CT to patients with stage III/IV and recurrent melanoma and 
referral of clinically node negative non-metastatic cases may 
be viewed as inappropriate allocation of resources.  Only 
three of 12 stage (25%) N0M0  referrals were upstaged, 
two of which were T4. Two were upstaged from stage II to 
III but one was upstaged from stage II (T4bN0M0) to IV 
(T4bN3M1c). The study results confirm the validity of our 
current protocol and the high proportion of patients referred 
for PET-CT with stage 0-II disease reflects a need for 
centralised discussion and multidisciplinary review prior to 
further staging investigations. 
Although survival outcomes were not analysed in this study, 
previous literature suggests that in clinically stage III disease 
PET-CT positivity is independently predictive of worse 
melanoma specific survival.17 A survival benefit is suggested 
with PET-CT staging and Dalrymple-Hay et al. published 
improved survival rates thought to be due to improved patient 
selection for surgery.19,20 In an advancing era of systemic 
targeted and immunotherapy, it may be considered that this 
benefit is underestimated and the need for accurate staging 
in advanced and recurrent disease is pivotal to outcome. In 
the South African public health setting it may be considered 
extravagant to direct resources towards expensive staging 
investigations such as PET-CT. However, immunotherapy 
is unlikely to be accessible in such settings and it remains 
paramount that oligometastatic patients amenable to 
metastasectomy be found with the aid of PET-CT. 
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A major limitation of this study was its retrospective nature. 
This poses the risk of selection bias, especially in the absence 
of a mitigating multivariate analysis, which was not possible 
due to small numbers. Prospective trials are lacking and further 
evidence is needed to justify the routine use of PET-CT over 
conventional imaging. Of note in our study, comparative cross-
sectional imaging was not standard and it was not possible to 
conclude the absolute benefit of PET-CT over conventional 
CT imaging. Available studies do however suggest that PET-
CT is more sensitive and specific than conventional CT.19,21 
Departmental protocols should be individualised according 
to resources. PET-CT is an expensive imaging tool, however 
in light of the cost-effectiveness of facilitating appropriate 
management in advanced and recurrent melanoma, its use 
may be justified.
A high number of exclusions resulted in fewer cases 
amenable to analysis which limited the power of our study. 
This was in part due to incomplete records and patients lost 
to follow-up. Poorly completed baseline records precluded 
satisfactory data collection to draw conclusions on the 
association of individual histopathological factors and a 
change in stage. Patient characteristics including ethnicity, 
HIV status and LDH levels were poorly recorded in clinical 
records. These are noteworthy omissions, given that ethnicity 
influences the incidence of melanoma,22 and HIV status 
influences the specificity of PET-CT findings.23 LDH levels 
are important to stage M1 disease according to AJCC 7th 
Ed. staging. Our findings are useful to direct accurate future 
clinical record keeping which would allow future research in 
our unique clinical setting. Further limitation was that PET-
CT findings confirming upstaging or down-staging were not 
correlated with pathological findings. 
Future directions as to whether Breslow depth and the 
presence or absence of ulceration justifies staging with PET-
CT in node negative disease and stratifying results for HIV 
positive individuals are necessary. A correlation analysis 
would aid in defining the individual risk of a change in stage 
and management. 
Conclusion
The results of our study favour the utility of PET-CT in the 
staging of advanced and recurrent melanoma. In this study 
a change in stage occurred in just over half of the entire 
cohort, and in 68.2% of the advanced and recurrent melanoma 
subset. PET-CT may effect a change in stage with clinical 
consequences, which was the case in 86.7% of patients with 
advanced and recurrent melanoma. It is our recommendation 
that PET-CT should be used as baseline imaging for stage III, 
IV and recurrent melanoma, which is in keeping with current 
guidelines. This remains relevant in resource limited settings, 
taking into account that accurate imaging effects changes in 
management. Appropriate selection of patients for PET-CT 
should take place within the context of a multidisciplinary 
team to ensure appropriate evidence-based care. It is clear that 
rigorous record keeping and adherence to clinical guidelines 
should be advocated in order to ensure optimal management 
and strengthen further research.
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